Ammonia N 13

CHEMBL1201189 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
16.0 g/mol
LogP
-0.7
Phase
4

A radioactive form of ammonia used as a tracer during positron emission tomography (PET) scans to evaluate blood flow to the heart muscle. It helps doctors identify areas of reduced circulation that may indicate coronary artery disease.

Moleküler Ağırlık

16,0300 g/mol

LogP

-0,70

TPSA

1,00 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[13NH3]

InChI

InChI=1S/H3N/h1H3/i1-1

Molecular Formula

H3N

HBD / HBA

1 / 1

Döndürülebilir Bağlar

0

Ağır Atomlar

1

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A radioactive form of ammonia used as a tracer during positron emission tomography (PET) scans to evaluate blood flow to the heart muscle. It helps doctors identify areas of reduced circulation that may indicate coronary artery disease.

Yes, Ammonia N 13 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201189. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 119432. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.